Statins and the Cardio-Hepatic Axis: Balancing Cardiovascular Protection with Liver Disease Safety

Statins, traditionally viewed with caution in liver disease due to concerns about hepatotoxicity, are now increasingly recognized as both safe and potentially beneficial in this population. Recent evidence demonstrates that clinically significant liver injury from statins is exceedingly rare, while mild aminotransferase elevations are usually transient and adaptive. Large trials and real-world studies confirm that patients with chronic liver disease, including nonalcoholic fatty liver disease, viral hepatitis, and compensated cirrhosis, tolerate statins well. Importantly, statins offer more than lipid-lowering: pleiotropic effects such as improved endothelial function, antifibrotic activity, and reductions in portal hypertension may alter the natural history of liver disease. In nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, statins not only provide substantial cardiovascular risk reduction but also improve aminotransferases and may slow fibrosis progression. In chronic viral hepatitis B and C, statin exposure is associated with slower fibrosis progression, fewer decompensations, and significant reductions in hepatocellular carcinoma risk, with dose-response relationships supporting causality. In alcoholic liver disease and cirrhosis, statins have been linked to lower mortality and decompensation, mediated in part by reductions in portal pressure, though caution is warranted in advanced decompensated states. Postliver transplant, statins are commonly indicated for dyslipidaemia and are associated with improved patient and graft survival when managed alongside immunosuppressant interactions. Overall, statins should be considered safe allies in patients with chronic liver disease, offering cardiovascular protection and potential hepatic benefits, shifting the paradigm from foe to friend.